Cited by 756Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Open access

Meyers, Paul A., Schwartz, Cindy L., Krailo, Mark D., Healey, John H., Bernstein, Mark L., Betcher, Donna, Ferguson, William S., Gebhardt, Mark C., Goorin, Allen M., Harris, Michael, Kleinerman, Eugenie, Link, Michael P., Nadel, Helen, Nieder, Michael, Siegal, Gene P., Weiner, Michael A., Wells, Robert J., Womer, Richard B., Grier, Holcombe E.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2008.14.0095

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 × 2 factorial design. The primary end points for analysis were EFS and overall survival. Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96). Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.14.0095

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,034
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citation
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
Souhami, R. L., Craft, A. W., van der Eijken, J. W., Nooij, M. A., Spooner, D. A., Bramwell, V. H. C., Wierzbicki, R. F., MALCOLM, A. J., Kirkpatrick, A., Uscinska, B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 381

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 401–500 of 756

Osteosarcoma
Lin, P. P., & PATEL, S. R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5194-5_5 · Cited by 16
Improving Osteosarcoma Treatment: Comparative Oncology in Action
Tarone, L., Mareschi, K., Tirtei, E., Giacobino, D., Camerino, M., Buracco, P., Morello, E. M., Cavallo, F., & Riccardo, F. (2022) · Life · doi:10.3390/life12122099 · Cited by 15
Current topics and management of head and neck sarcomas
Kobayashi, K., Hanai, N., Yoshimoto, S., Saito, Y., & Homma, A. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad048 · Cited by 16
Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma
Feng, J., Wang, J., Xu, Y., Lu, F., Zhang, J., Han, X., Zhang, C., & Wang, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288180 · Cited by 15
A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers
Venkatakrishnan, K., Kramer, W. G., Synold, T. W., Goodman, D. B., Sides, E. H., & Oliva, C. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1262-1 · Cited by 15
Immunotherapy in Pediatric Malignancies: Current Status and Future Perspectives
Capitini, C. M., Otto, M., DeSantes, K. B., & Sondel, P. M. (2014) · Future Oncology · doi:10.2217/fon.14.62 · Cited by 15
BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model
Xiong, Q., Wang, X., Wang, L., Huang, Y. X., Tian, X., Fan, Y., & Lin, C.-Y. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s176724 · Cited by 15
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression
Sugiu, K., Tazawa, H., Hasei, J., Yamakawa, Y., Omori, T., Komatsubara, T., Mochizuki, Y., Kondo, H., Osaki, S., Fujiwara, T., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04310-5 · Cited by 16
Ifosfamide in the Neoadjuvant Treatment of Osteogenic Sarcoma
Maki, R. G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3285 · Cited by 15
Osteosarcoma through the Lens of Bone Development, Signaling, and MicroenvironmentPreprint
Young, E. P., Marinoff, A. E., López-Fuentes, E., & Sweet-Cordero, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041635 · Cited by 14
Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
Mason, N. J., Selmic, L. E., Ruple, A., London, C. A., Barber, L. G., Weishaar, K. M., Perry, J. A., Mahoney, J., Flesner, B. K., Bryan, J. N., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.023 · Cited by 14
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers
Li, D., & Rudloff, U. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2504376 · Cited by 15
Fifty years of bone tumors
Bartelstein, M. K., & Boland, P. J. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27027 · Cited by 14
Ubiquitin specific peptidase 37 and PCNA interaction promotes osteosarcoma pathogenesis by modulating replication fork progression
Chauhan, R., Gupta, A., Malhotra, L., Bhat, A. A., PANDITA, R. K., Masoodi, T., Dagar, G., Sadida, H. Q., Al-Marzooqi, S. K., Batra, A., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04126-2 · Cited by 14
Osteosarcoma-Approach to Therapy
Bielack, S., Cable, M. G., Gorlick, R. G., Hecker‐Nolting, S., Kager, L., Marina, N. M., Randall, R. L., & Whelan, J. S. (2020) · Pediatric oncology · doi:10.1007/978-3-030-51160-9_8 · Cited by 14
Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma
Mills, L. J., Scott, M. C., Shah, P., Cunanan, A. R., Deshpande, A., Auch, B., Curtin, B., Beckman, K. B., Spector, L. G., Sarver, A. L., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115716 · Cited by 14
Analysis of Immune Gene Expression Subtypes Reveals Osteosarcoma Immune Heterogeneity
Wan, B., Wang, R., Nie, J., Sun, Y., Zhang, B., Liu, W., & Chen, D. (2021) · Journal of Oncology · doi:10.1155/2021/6649412 · Cited by 13
RETRACTED ARTICLE: S100 calcium-binding protein A10 contributes to malignant traits in osteosarcoma cells by regulating glycolytic metabolism via the AKT/mTOR pathway
Ling, F., & Lu, Q. (2022) · Bioengineered · doi:10.1080/21655979.2022.2071022 · Cited by 14
Retracted
Analysis of Chemotherapy Dosage and Dosage Intensity and Survival Outcomes of High-Grade Osteosarcoma Patients Younger Than 40 Years
Sun, L., Li, Y., Li, H., Zhang, J., Li, B., & Ye, Z. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.02.018 · Cited by 14
Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways
Zhuo, B., Shi, Y., Qin, H., Sun, Q., Li, Z., Zhang, F., Wang, R., & Wang, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5990 · Cited by 14
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Palmerini, E., Meazza, C., Tamburini, A., Márquez-Vega, C., Bisogno, G., Fagioli, F., Ferraresi, V., Milano, G. M., Coccoli, L., Rubio‐San‐Simón, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00210 · Cited by 13
Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche
Reinecke, J. B., Garcia, L. J., Saraf, A. J., Hinckley, J., Gross, A. C., Pommellet, H. L., Gutpell, K. M., Cam, M., Cannon, M. V., Gust, M. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3360 · Cited by 13
Targeted therapy for soft tissue sarcomas in adolescents and young adults
Steppan, D. A., Pratilas, C. A., & Loeb, D. M. (2017) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s70377 · Cited by 13
Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
Akazawa, Y., Hosono, A., Yoshikawa, T., Kaneda, H., Nitani, C., Hara, J., Kinoshita, Y., Kohashi, K., Manabe, A., Fukutani, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14206 · Cited by 13
Current treatment landscape and emerging management options for extremity sarcoma
Turkar, S. (2018) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_9_19 · Cited by 13
Optimizing preclinical study design in oncology research
Wittenburg, L. A., & Gustafson, D. L. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.01.029 · Cited by 13
Nucleosome-binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2-OS osteosarcoma cell lines
Liang, G., Xu, E., Yang, C., ZHANG, C., Sheng, X., & Zhou, X. (2014) · Oncology Reports · doi:10.3892/or.2014.3689 · Cited by 13
Immune Therapy for Sarcomas
Anderson, P. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_6 · Cited by 13
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma
Robl, B., Botter, S. M., Boro, A., Meier, D., Neri, D., & Fuchs, B. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.02.005 · Cited by 13
miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases
Yang, Y., Huang, G., Zhou, Z., Fewell, J. G., & Kleinerman, E. S. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0042 · Cited by 14
Self-citation
Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma
Tang, Q.-X., Wang, L., Wang, Y., Gao, H.-D., & Hou, Z.-L. (2019) · Medicine · doi:10.1097/md.0000000000014442 · Cited by 13
Overexpression of microRNA-495 suppresses the proliferation and invasion and induces the apoptosis of osteosarcoma cells by targeting high-mobility group nucleosome-binding domain 5
Jiang, W., Zheng, J., Tao, Y., & Wang, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5715 · Cited by 12
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
Anderson, P. M., Subbiah, V., & Trucco, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1030094 · Cited by 12
From biology to personalized medicine: Recent knowledge in osteosarcoma
Mohr, A., Costa, M. E. M. D., Fromigué, O., Audinot, B., Balde, T., Droit, R., Abbou, S. D., Khneisser, P., Berlanga, P., Pérez, E., et al. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104941 · Cited by 13
The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma
Wu, D., Yin, H., Yang, C., Zhang, Z.-M., Fang, F., Wang, J., Li, X., Xie, Y., Hu, X., Zhuo, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12691-y · Cited by 12
CD103+ cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases
Yang, Y., Zhou, Y., Wang, J., Zhou, Y. L., Watowich, S. S., & Kleinerman, E. S. (2024) · Cancers · doi:10.3390/cancers16193251 · Cited by 12
Self-citation
Contemporary surgical management of osteosarcoma and Ewing sarcoma
Callan, A. K., Alexander, J. H., Montgomery, N. I., Lindberg, A. W., Scharschmidt, T. J., & Binitie, O. T. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31374 · Cited by 12
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
Hiraga, H., Machida, R., Kawai, A., Kunisada, T., Yonemoto, T., Endo, M., Nishida, Y., Nagano, A., Ae, K., Yoshida, S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01281 · Cited by 12
Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility
Zhang, Y., Hu, X., Wang, H., Shen, W., Liao, T., Chen, P. C., & Chu, T. (2014) · Tumor Biology · doi:10.1007/s13277-014-2591-8 · Cited by 12
Retracted Article: Macrophage-derived exosomes mediate osteosarcoma cell behavior by activating AKT signaling
Yan, B., Liu, Q., Liu, G., Huang, X., Zhu, G., Gao, L., & Xu, Y. (2020) · RSC Advances · doi:10.1039/c9ra07332a · Cited by 12
Retracted
A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients
Longhi, A., Mariani, E., & Kuehn, J. J. (2009) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2009.02.005 · Cited by 12
Risk-Based Therapy for Localized Osteosarcoma
Venkatramani, R., Murray, J. C., Helman, L. J., Meyer, W. H., Hicks, J. M., Krance, R. A., Lau, C. C., Jo, E., & Chintagumpala, M. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25808 · Cited by 12
Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma
Verschoor, A. J., Speetjens, F. M., Dijkstra, P. D. S., Fiocco, M. F., van de Sande, M. A. J., Bovée, J. V. M. G., & Gelderblom, H. A. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0528 · Cited by 12
Non-rodent animal models of osteosarcoma: A review
Jarvis, S., Koumadoraki, E., Madouros, N., Sharif, S., Saleem, A., & Khan, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100307 · Cited by 12
Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab
Zhao, Z., Li, X., Liu, W., Liu, X., Wu, S., & Hu, X. (2016) · Orthopaedic Surgery · doi:10.1111/os.12236 · Cited by 12
Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor
Bozzo, A., Yeung, C. M., van de Sande, M. A. J., Ghert, M. A., Healey, J. H., & on behalf of the PARITY Investigators (2023) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.01231 · Cited by 13
Self-citation
Translational History and Hope of Immunotherapy of Canine Tumors
Bryan, J. N., & Maitz, C. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2266 · Cited by 11
STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis
Shrestha, P., Shrestha, R., Zhou, Y. L., Zielinski, R. J., Priebe, W., & Kleinerman, E. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608375 · Cited by 13
Self-citation
The Current Landscape of Early Drug Development for Patients with Sarcoma in the Immunotherapy Era
Sebio, A., Wilky, B. A., Keedy, V. L., & Jones, R. L. (2018) · Future Oncology · doi:10.2217/fon-2017-0565 · Cited by 11
Maintenance therapy and drug holiday in sarcoma patients: systematic review
Lebellec, L., Defachelles, A. S., Cren, P., & Penel, N. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1759825 · Cited by 11
The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand
Sirikul, W., Buawangpong, N., Pruksakorn, D., Charoentum, C., Teeyakasem, P., & Koonrungsesomboon, N. (2023) · Cancers · doi:10.3390/cancers15071979 · Cited by 11
MR Imaging of Pediatric Musculoskeletal Tumors:
Lee, M., Chhabra, A. B., Pressey, J. G., Dumoulin, C. L., & Kim, H. K. (2019) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2019.01.010 · Cited by 11
The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets
Belayneh, R., & Weiss, K. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_10 · Cited by 11
Enzyme-instructed morphology transformation of mitochondria-targeting peptide for the selective eradication of osteosarcoma
Jeena, M. T., Jin, S., Jana, B., & Ryu, J. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00166g · Cited by 11
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma
Pascual‐Pasto, G., Resa‐Pares, C., Castillo‐Ecija, H., Aschero, R., Baulenas‐Farres, M., Vilà-Ubach, M., Burgueño, V., Balaguer‐Lluna, L., Cuadrado‐Vilanova, M., Olaciregui, N. G., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115408 · Cited by 11
Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone
Wang, Y., Liu, M., Yang, P. H., & Peng, H. (2018) · Medical Science Monitor · doi:10.12659/msm.908736 · Cited by 10
Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional
Borgatti, A., Dickerson, E. B., & Lawrence, J. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12554 · Cited by 11
Dog Models of Naturally Occurring Cancer
Fenger, J. M., Rowell, J., Zapata, I., Kisseberth, W. C., London, C. A., & Alvarez, C. E. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527695881.ch9 · Cited by 11
Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses
Zheng, H., & Zhan, H. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00323-8 · Cited by 10
Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma
Hansen, A. R., Hughes, B. G. M., Paul, S. K., Steadman, P., Sommerville, S. M. M., Dickinson, I. C., Walpole, E. T., Thomson, D. B., Fan, H. M., & Joubert, W. L. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12167 · Cited by 10
Advanced Cancer Imaging Applied in the Comparative Setting
Vail, D. M., LeBlanc, A. K., & Jeraj, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00084 · Cited by 11
Management of pelvic sarcoma
Lee, J. S.-J., Kelly, C. M., & Bartlett, E. K. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.09.011 · Cited by 10
New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Janeway, K. A., & Maki, R. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0875 · Cited by 11
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation
Armstrong, A. E., Walterhouse, D. O., Leavey, P. J., Reichek, J. L., & Walz, A. L. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27493 · Cited by 10
Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene
Messerschmitt, P. J., Rettew, A. N., Schroeder, N. O., Brookover, R. E., Jakatdar, A., Getty, P. J., & Greenfield, E. M. (2012) · Sarcoma · doi:10.1155/2012/479712 · Cited by 11
Of Mice and Men: Opportunities to Use Genetically Engineered Mouse Models of Synovial Sarcoma for Preclinical Cancer Therapeutic Evaluation
Jones, K. B., Haldar, M., Schiffman, J. D., Cannon‐Albright, L., Lessnick, S. L., Sharma, S., Capecchi, M. R., & Randall, R. L. (2011) · Cancer Control · doi:10.1177/107327481101800307 · Cited by 10
Mammalian models of bone sarcomas
Botter, S. M., Arlt, M., Born, W., & Fuchs, B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00030-3 · Cited by 10
Diagnosis and management of primary malignant tumors in the upper extremity
MacKay, B. J., McCormack, R. A., Blank, A. T., Bettiol, P., Cox, C. T., Brindley, G. W., & Rapp, T. B. (2021) · Orthopedic Reviews · doi:10.4081/or.2020.8345 · Cited by 9
Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines
Yang, Y.-T., & Yuzbasiyan‐Gurkan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169345 · Cited by 9
Chemotherapy Regimens for Patients with Newly Diagnosed Malignant Bone Tumors
Roberts, R. D., Wedekind, M. F., & Setty, B. A. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_6 · Cited by 9
Spontaneous Companion Animal (Pet) Cancers
Vail, D. M., & Thamm, D. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_15 · Cited by 9
HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies
Geller, D. S., & Gorlick, R. G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903419614 · Cited by 9
Emerging cytokine networks in osteosarcoma
Lopes‐Júnior, L. C., da Silveira, D. S. C., Vulczak, A., dos Santos, J. C., Veronez, L. C., Fisch, A., Flória‐Santos, M., de Lima, R. A. G., & da Silva, G. P. (2016) · Cited by 9
Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
Calaminus, G., Jenney, M. E. M., Hjorth, L., Baust, K., Bernstein, M. L., Bielack, S., Vos, P. D., Hogendoorn, P. C. W., Jovic, G., Krailo, M., et al. (2019) · JMIR Research Protocols · doi:10.2196/14406 · Cited by 9
Self-citation
Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse
Longhi, A., Cesari, M., Serra, M., & Mariani, E. (2020) · Sarcoma · doi:10.1155/2020/8260730 · Cited by 9
The perplexing role of immuno-oncology drugs in osteosarcoma
Smrke, A., Tam, Y. B., Anderson, P. M., Jones, R. L., & Huang, P. H. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100400 · Cited by 9
Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective
Mittal, A., Pushpam, D., Ganguly, S., Kumar, V. S., Khan, S. A., & Bakhshi, S. (2022) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01486-3 · Cited by 11
Skeletal imaging effects of pamidronate therapy in osteosarcoma patients
Price, A. P., Abramson, S. J., Hwang, S., Chou, A. J., Bartolotta, R. J., Meyers, P. A., & Katz, D. S. (2010) · Pediatric Radiology · doi:10.1007/s00247-010-1883-4 · Cited by 9
Self-citation
Osteosarcoma segmentation in CT images based on hybrid relative fuzzy connectedness
Chen, C., Ding, S., Wu, Q., Li, N., & Wu, S. (2012) · International Conference on Biomedical Engineering and Informatics (BMEI) · doi:10.1109/bmei.2012.6512993 · Cited by 9
Gene-Based Therapies for Cancer
Roth, J. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6102-0 · Cited by 9
Osteosarcoma
Tattersall, L., Davison, Z., & Gartland, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62259-6 · Cited by 10
IL-11Rα: A Novel Target for the Treatment of Osteosarcoma
Lewis, V. O. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_15 · Cited by 8
Immune Environment and Osteosarcoma
Heymann, M., & Heymann, D. (2017) · InTech eBooks · doi:10.5772/67448 · Cited by 8
Assessment of Risk of Bias in Osteosarcoma and Ewing’s Sarcoma Randomized Controlled Trials: A Systematic Review
Koucheki, R., Gazendam, A., Perera, J. R., Griffin, A. M., Ferguson, P. C., Wunder, J. S., & Tsoi, K. M. (2021) · Current Oncology · doi:10.3390/curroncol28050322 · Cited by 8
Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta‐analysis
Sun, X., & Guo, W. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13629 · Cited by 8
Fifty Years of Advances in Sarcoma Treatment: Moving the Needle from Conventional Chemotherapy to Targeted Therapy
PATEL, S. R. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.259 · Cited by 8
Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma
Brosa, M., del Muro, X. G., Mora, J., Villacampa, A., Pozo-Rubio, T., Cubells, L., & Montoto, C. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.972378 · Cited by 8
New drugs in sarcomas
Martín-Liberal, J., Benson, C., & Judson, I. R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.865015 · Cited by 7
Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Giordano, G., Tucciarello, C., Merlini, A., Cutrupi, S., & Pignochino, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01811-7 · Cited by 8
The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis
Song, H. J., Lee, E., Lee, J. A., Kim, H.-L., & Jang, K. W. (2014) · Tumor Biology · doi:10.1007/s13277-014-2139-y · Cited by 7
Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma
Reinecke, J. B., & Roberts, R. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_7 · Cited by 7
Construction of survival-related co-expression modules and identification of potential prognostic biomarkers of osteosarcoma using WGCNA
Bian, Y., Huang, J., Zeng, Z., Yao, H., Tu, J., Wang, B., Zou, Y., Xie, X., & Shen, J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-399 · Cited by 6
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
Nastasi, N., Pasha, A., Bruno, G., Subbiani, A., Pietrovito, L., Leo, A., Scala, L., de Simone, L., Casazza, G., Lunardi, F., et al. (2023) · Cancers · doi:10.3390/cancers15194744 · Cited by 7
Highlights of the First International “Immunotherapy in Pediatric Oncology: Progress and Challenges” Meeting
Capitini, C. M., Cooper, L. J. N., Egeler, R. M., Handgretinger, R., Locatelli, F., Sondel, P. M., & Mackall, C. L. (2009) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31819a5d8d · Cited by 7
Current clinical trials for advanced osteosarcoma and soft tissue sarcoma
Sleijfer, S., & Gelderblom, H. A. J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000093 · Cited by 7
Bronchioloalveolar carcinoma as a second malignancy in osteosarcoma survivors
Lebensburger, J. D., Katzenstein, H. M., Jenkins, J. J., & Galindo, C. R. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22005 · Cited by 7
Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity
Sukhatme, V. V., Ramalingam, S. S., Ahmed, R., & Sukhatme, V. P. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000368 · Cited by 7
Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience
Taçyıldız, N., Ünal, E., Dincaslan, H. U., Çakmak, H. M., Köse, K., Tanyıldız, H. G., & Kartal, Ö. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.3.715 · Cited by 7
Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
Martín‐Broto, J., Hindi, N., Aguiar, S., Badilla, R., Oliden, V. C., Chacon, M. R., Generoso, R. C., de Álava, E., Donati, D. M., Eriksson, M., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0516 · Cited by 7
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis
Kokkali, S., Kotsantis, I., Magou, E., Talagani, S., Kormas, T., Diakoumis, G., Spathas, N., Psyrri, A. K., & Ardavanis, A. S. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01225-7 · Cited by 7

Authors: Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., Kleinerman, E., Link, M. P., Nadel, H., Nieder, M., Siegal, G. P., Weiner, M. A., Wells, R. J., Womer, R. B., & Grier, H. E.
Affiliations: Children's Oncology Group (US)
ORCID: Meyers, Paul A.
Schwartz, Cindy L.
Krailo, Mark D.
Healey, John H.
Bernstein, Mark L.
Ferguson, William S.
Kleinerman, Eugenie
Nadel, Helen
Siegal, Gene P.
Womer, Richard B.
Grier, Holcombe E.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-02-01
Volume: 26
Issue: 4
Pages: 633-638
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.14.0095
OpenAlex: W2103405666
Cited by: 752
References: 20
Citations by year: 2026: 21 · 2025: 30 · 2024: 30 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 70 · 2019: 39 · 2018: 38 · 2017: 55 · 2016: 49 · 2015: 50 · 2014: 57 · 2013: 46 · 2012: 36
FWCI: 33.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Children’s Oncology Group
National Institutes of Health (CA98543)
National Cancer Institute (U10CA098543, CA-98543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: osteosarcoma, muramyl tripeptide, ifosfamide, cisplatin, doxorubicin, methotrexate, event-free survival, overall survival, pediatric cancer chemotherapy, immunomodulatory therapy, surgical resection
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Doxorubicin, Female, Humans, Ifosfamide, Infant, Lung Neoplasms, Male, Methotrexate, Neoplasm Recurrence, Local, Osteosarcoma, Survival Rate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks